Every 8-K that ZYVERSA THERAPEUTICS INC (ZVSA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ZVSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZVSA filings page.
ZyVersa Therapeutics, Inc. reports a change in the trading venue for its common stock. Effective July 16, 2026, the company’s common stock, par value $0.0001 per share and trading under the symbol ZVSA, ceased trading on the OTCQB® Venture Market and commenced trading on the OTC Pink Limited Market.
ZyVersa Therapeutics, Inc. reported that on July 8, 2026, independent director Min Chul Park, Ph.D. resigned from the Board, the Compensation Committee, and the Nominating and Corporate Governance Committee for personal reasons, with no disagreement related to operations, policies, or practices. The company’s leadership has begun implementing and evaluating cost-cutting measures while seeking to raise capital. The CEO and CFO have voluntarily accepted reduced compensation to conserve cash and increase balance sheet flexibility. Potential additional actions include divesting or selling the VAR 200 or IC 100 product candidates, reducing employee headcount, and decreasing public-company expenses, which may include “going dark” by suspending reporting obligations under Sections 13(a) and 15(d) via Rule 12h-3. ZyVersa is also considering broader strategic alternatives such as a sale of the company or its assets, or a restructuring or reorganization, aiming to extend operations while pursuing new financing.
ZyVersa Therapeutics entered into a Securities Purchase Agreement with accredited investors for a private placement of $1 million in convertible promissory notes and accompanying Series A-4 common stock purchase warrants. The notes bear 10% annual interest, mature 12 months after issuance, and are convertible into common stock at 80% of either the price in a future Qualified Offering or the lowest 10-day volume-weighted average price before conversion, subject to a $0.02 per share floor. The five-year warrants become exercisable six months after issuance, with an exercise price set at 110% of the Qualified Offering price or a VWAP-based level, and the share amount per warrant equals 50% of each investor’s subscription amount divided by the exercise price. ZyVersa agreed to file resale registration statements for the underlying shares within specified timeframes and to limit dividends, redemptions, and variable-rate transactions while the securities are outstanding. Net proceeds are intended for working capital, and obligations under the notes are guaranteed by a wholly owned subsidiary.
ZyVersa Therapeutics, Inc. reported that independent director Robert G. Finizio has resigned from the company’s Board of Directors, effective immediately. He also stepped down as Chairman of the Compensation Committee and as a member of the Audit Committee. The company states that his resignation is due to personal reasons and is not the result of any disagreement regarding ZyVersa’s operations, policies, or practices. ZyVersa’s common stock, par value $0.0001 per share, is quoted on the OTCQB Venture Market under the symbol ZVSA.
ZyVersa Therapeutics, Inc. (ZVSA) filed a current report to announce that it released a press release with its unaudited financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is being furnished rather than filed, which means it is not automatically subject to certain liability provisions under the securities laws or incorporated into other securities filings unless specifically referenced. The company’s common stock, par value $0.0001 per share, trades under the symbol ZVSA and is quoted on the OTCQB Venture Market.
ZyVersa Therapeutics announced a leadership change. On October 10, 2025, Pablo Guzman, M.D., resigned as Chief Medical Officer and Senior Vice President of Medical Affairs. Dr. Guzman joined the company in January 2015 after more than 35 years practicing interventional cardiology in South Florida and serving as a managing partner of Cardiology Associates of Fort Lauderdale. The company states he resigned to spend more time with his family and to travel.
ZyVersa Therapeutics, Inc. reports that the Nasdaq Stock Market plans to delist its common stock following the filing of a Form 25 with the SEC on or about September 18, 2025. The delisting will become effective ten days after the Form 25 is filed under Exchange Act Rule 12d2-2.
The company’s common stock was suspended from trading on The Nasdaq Capital Market on July 17, 2025 after failing to regain compliance with Nasdaq’s minimum bid price requirement, and it has been trading on the OTCQB Venture Market under the symbol “ZVSA” since July 28, 2025. ZyVersa states that its common stock will continue trading on the OTCQB without disruption.
ZyVersa Therapeutics (NASDAQ:ZVSA) has entered into a significant Equity Purchase Agreement with Williamsburg Venture Holdings. The agreement provides ZyVersa with the right to sell up to $10 million of common stock through June 24, 2027. The purchase price will be set at 94% of the lowest traded Volume-Weighted Average Price during a 3-day period after share issuance.
Key terms include a 2.5% commitment fee in additional shares, issuance limitations of 19.99% of outstanding shares without stockholder approval, and mandatory registration of shares within 120 days. The company will maintain control over the timing and amount of any sales based on market conditions and financing needs.